Learn more →
Back to Expert Scholars
basic / basicPediatric Oncology

Chris Jones

克里斯·琼斯

PhD

🏢Institute of Cancer Research (ICR), London(伦敦癌症研究所)🌐UK

Professor of Paediatric Brain Tumour Biology; Team Leader, Glioma Team儿童脑肿瘤生物学教授;胶质瘤研究团队负责人

53
h-index
3
Key Papers
5
Awards
3
Key Contributions

👥Biography 个人简介

Chris Jones is a leading ICR researcher and world authority on DIPG and pediatric glioma epigenomics, who made foundational contributions to characterizing H3K27M biology, established the most comprehensive DIPG genomic dataset in Europe, and translates molecular insights into actionable clinical trial hypotheses.

Share:

🧪Research Fields 研究领域

DIPG EpigenomicsDIPG表观基因组学
H3K27M BiologyH3K27M生物学
Pediatric Glioma Drug Resistance儿童胶质瘤耐药性
Translational Brain Tumor Research脑肿瘤转化研究

🎓Key Contributions 主要贡献

DIPG Epigenomic Landscape

Generated comprehensive H3K27M DIPG epigenomic maps revealing global redistribution of H3K27me3 and H3K27ac, identifying super-enhancer-driven oncogenes as therapeutic targets.

DIPG Drug Resistance Mechanisms

Characterized molecular mechanisms of resistance to ONC201 and panobinostat in DIPG, including compensatory chromatin remodeling and kinase pathway rewiring driving treatment failure.

Multi-Omic DIPG Biobank

Established the UK's largest DIPG biobank with matched diagnostic, post-irradiation, and autopsy samples enabling longitudinal study of disease evolution and resistance development.

Representative Works 代表性著作

[1]

Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma

Nature Genetics (2014)

Co-discovered recurrent ACVR1 mutations as a second founding alteration in H3K27M DIPG, opening BMP pathway as a therapeutic target.

[2]

Comprehensive epigenomic analysis of H3K27M DIPG reveals super-enhancer reprogramming

Cancer Cell (2019)

Defined the global H3K27M-driven epigenomic landscape in DIPG, identifying super-enhancer-driven oncogenes amenable to BET bromodomain inhibition.

[3]

Acquired resistance mechanisms to ONC201 in H3K27M diffuse midline glioma

Nature Communications (2024)

Identified ClpP activator resistance mechanisms and combination strategies to overcome ONC201 resistance in DMG.

🏆Awards & Recognition 奖项与荣誉

🏆Children with Cancer UK Research Prize
🏆Brain Tumour Research Innovation Award
🏆Cancer Research UK Programme Grant
🏆ISNO Outstanding Science Award
🏆Wellcome Trust Investigator Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 克里斯·琼斯 的研究动态

Follow Chris Jones's research updates

留下邮箱,当我们发布与 Chris Jones(Institute of Cancer Research (ICR), London)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment